Memory Pharmaceuticals Corp.

Jzaneen Lalani has served as our Vice President, Legal Affairs since June 2004. From February 2003 to May 2004, Ms. Lalani was a member of the Corporate and Commercial Law Group at Kronish Lieb Weiner & Hellman LLP, where she worked with privately held and publicly traded companies on transactions including mergers and acquisitions, financings and securities offerings. From October 1999 to February 2003, Ms. Lalani was a member of the Business & Technology Group at Brobeck Phleger & Harrison LLP, where her practice also included representing emerging growth companies and newly-public companies. Ms. Lalani received a B.Sc. in 1993 from Queen s University in Ontario, her LL.B. in 1996 from the University of Victoria, in British Columbia, and a Master of International Affairs and a Masters of Law from Columbia University in 1999. Ms. Lalani is admitted to the British Columbia Bar and the New York Bar and is licensed as an in-house counsel in the State of New Jersey.

Michael P. Smith, Vice President of Business Development. From 2004 to 2006, Mr. Smith served as Vice President of Business Development for QLT, Inc., a global biopharmaceutical company, where he was responsible for all business development activities as well as corporate strategy. From 1998 to 2004, Mr. Smith was with Chiron Corporation, a biotechnology company, where he held several senior positions, including Manager, Corporate Finance and Business Development and Director Corporate Development, and was responsible for developing and implementing M&A and strategic partnership transactions and strategies. Prior to joining Chiron Corporation, Mr. Smith was the Finance/Business Development Manager for Ascent Logic Corporation, a private systems engineering software company. Mr. Smith holds a B.S. from the University of Virginia, as well as an MBA from the University of California, Berkeley.

Jonathan J. Fleming is one of our co-founders and is Chairman of our Board of Directors. Mr. Fleming served as Chairman from January 1998 to May 2005 and assumed the position again in October 2006. Mr. Fleming has served as the Managing Partner of Oxford Bioscience Partners, a venture capital firm specializing in life science technology since 1996. Prior to joining Oxford Bioscience, he served as a Founding Partner of MVP Ventures in Boston, Massachusetts. Mr. Fleming serves as a member of the board of directors of Imcor Pharmaceutical Co. (formerly Photogen Technologies, Inc.), a specialty pharmaceutical company focused on developing medical imaging pharmaceutical products. He also serves as Chairman of the board of directors of BioProcessors Corporation, a privately-held corporation, and as a director of seven other privately-held companies, including Leerink Swann & Company, Inc., a Boston-based investment bank specializing in health care companies. Mr. Fleming is a Trustee of the Museum of Science in Boston and is a Senior Lecturer at Massachusetts Institute of Technology's Sloan School of Management. Mr. Fleming received a B.A. from the University of California, Berkeley and a Masters in Public Administration from Princeton University.

Anthony B. Evnin, Ph.D. , a director since October 2006, is a General Partner of Venrock, a venture capital firm, where he has been a Partner since 1975. He is currently a member of the Board of Directors of Icagen, Inc., Infinity Pharmaceuticals, Inc and Sunesis Pharmaceuticals, Inc., as well as being on the Board of Directors of a number of private companies. Dr. Evnin received an A.B. in Chemistry from Princeton University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Larry R. Squire, Ph.D., University Professor, VA Medical Center in La Jolla, California, and a Professor at the University of California San Diego. Dr. Squire is a leading scientist in the field of human and non-human primate memory. A former President of the Society of Neuroscience, he has helped define the basic distinction between the declarative and non-declarative memory systems of the brain. Dr. Squire sits on the editorial board of Learning & Memory Journal and on the board of directors of the McKnight Endowment Fund for Neuroscience. He was elected Member of the National Academy of Science in 1993. He is the co-author of Memory, From Mind to Molecules.

Mark Leschly is managing partner of Rho Ventures and serves on the investment committees of Rho Fund Investors and Rho Private Equity. Prior to joining Rho in 1999, Leschly spent five years in venture capital at Healthcare Ventures where he was a general partner. Previously, he held a management consulting position at McKinsey & Company. Leschly received his masters in business administration from Stanford Graduate School of Business, and his current and recent board seats include: Anacor, Diversa (Nasdaq: DVSA), Inotek, Memory Pharmaceuticals (Nasdaq: MEMY), MPV, NitroMed (Nasdaq: NTMD), Orametrix, Orqis, Senomyx (Nasdaq: SNMX), SiTV, Tercica (Nasdaq: TRCA) and Vicuron (Nasdaq: MICU).

Richard Mayeux is the Gertrude H. Sergievsky Professor of Neurology, Psychiatry and Epidemiology at Columbia University. He is the director of the Gertrude H. Sergievsky Center and the co-director of the Taub Institute for Research on Alzheimer's Disease and the Aging Brain. Born in New Orleans, Louisiana, he is a graduate of Oklahoma State University and the University of Oklahoma Health Sciences, School of Medicine. He also holds a masters degree in Epidemiology from Columbia University. He completed residencies in both Internal Medicine (Boston City Hospital, Boston University) and Neurology (Columbia Presbyterian Medical Center, Columbia College of Physicians and Surgeons). He also completed post-doctoral training fellowship in Behavioral Neurology at the Boston Veterans Administration Medical Center (at Boston University) with D. Frank Benson, funded by the National Institute of Health.

Scott Small, M.D., Herbert Irving Assistant Professor in Neurology at Columbia University and Taub Scholar at the Taub Institute. With a background in cellular physiology, Dr. Small has focused on using new imaging modalities to investigate both normal and pathological mechanisms of the brain. Dr. Small was the first investigator at Columbia University to use functional magnetic resonace imaging (fMRI), and he led a team of investigators who published the first paper showing the utility of fMRI for detecting Alzheimer's disease and for characterizing memory decline in the aging population. More recently, he has developed a novel high-resolution application of fMRI, which can be used to investigate physiologic dysfunction in the mouse brain.